ERBB2 and breast cancer: Kaplan–Meier survival analysis showed that the median survival times of patients with HER2-positive, luminal A, luminal B, and triple-negative BC were 25 months (95% CI, 20–37), 27 months (95% CI, 23–29), 35 months (95% CI, 30–44), and 12 months (95% CI, 11–14), respectively [Figure 6].